文献速递生殖医学

一项III期随机对照试验:口服地屈孕酮与微粒化阴道黄体酮在体外受精黄体支持中的疗效、安全性和耐受性比较

A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization.
PubMed 文献 · Hum Reprod · 2017-01-01

Lotus I是一项在38个中心开展的III期随机对照试验,纳入1031例计划行IVF的不孕女性,比较口服地屈孕酮30 mg/日与微粒化阴道黄体酮600 mg/日进行黄体支持。结果显示,口服地屈孕酮在孕12周妊娠率方面非劣效于微粒化阴道黄体酮,妊娠率分别为37.6%和33.1%(差值4.7%;95%CI:-1.2-10.6%),且耐受性良好、安全性特征相似。

要点

  • 口服地屈孕酮30 mg/日(10 mg每日三次)在孕12周妊娠率方面非劣效于微粒化阴道黄体酮600 mg/日(200 mg每日三次)。
  • 孕12周妊娠率:地屈孕酮组37.6% vs 微粒化阴道黄体酮组33.1%(差值4.7%;95%CI:-1.2-10.6%)。
  • 活产率:地屈孕酮组34.6%(172位母亲,213名新生儿)vs 微粒化阴道黄体酮组29.8%(142位母亲,158名新生儿)(差值4.9%;95%CI:-0.8-10.7%)。

核心结论

  • 口服地屈孕酮30 mg/日(10 mg每日三次)在孕12周经阴道超声检测胎心方面非劣效于微粒化阴道黄体酮600 mg/日(200 mg每日三次)。
  • 口服地屈孕酮耐受性良好,安全性特征与微粒化阴道黄体酮相似。
  • 作者认为,口服地屈孕酮可能替代微粒化阴道黄体酮作为IVF黄体支持的标准治疗,因为口服途径比阴道给药对患者更友好,且耐受性好、有效。

研究设计与样本

  • Lotus I是一项国际III期随机对照试验,于2013年8月至2016年3月在38个中心开展。
  • 纳入标准为绝经前女性(>18至<42岁;BMI≥18至≤30 kg/m2),有记录的不孕史且计划行IVF。
  • 采用集中电子系统进行随机化,研究期间研究者、申办方研究团队和受试者均保持盲态。
  • 共随机分配1031例受试者,口服地屈孕酮组520例,微粒化阴道黄体酮组511例。
  • 黄体支持从取卵日开始,持续至孕12周(第10周),前提是胚胎移植后2周妊娠试验阳性。

主要发现

  • 孕12周妊娠率:口服地屈孕酮组37.6% vs 微粒化阴道黄体酮组33.1%(差值4.7%;95%CI:-1.2-10.6%),非劣效性成立。
  • 活产率:口服地屈孕酮组34.6%(172位母亲,213名新生儿)vs 微粒化阴道黄体酮组29.8%(142位母亲,158名新生儿)(差值4.9%;95%CI:-0.8-10.7%)。
  • 口服地屈孕酮耐受性良好,安全性特征与微粒化阴道黄体酮相似。

临床怎么用

  • 作者认为,口服地屈孕酮可能替代微粒化阴道黄体酮作为IVF黄体支持的标准治疗,因为口服途径比阴道给药对患者更友好,且耐受性好、有效。

局限性

  • 该研究的结果分析以临床妊娠率作为效能计算依据,但活产率可能具有更大的临床意义。
  • 因此,本研究观察到的治疗间活产率差异的结论应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is oral dydrogesterone 30 mg daily (10 mg three times daily [TID]) non-inferior to micronized vaginal progesterone (MVP) 600 mg daily (200 mg TID) for luteal support in in vitro fertilization (IVF), assessed by the presence of fetal heartbeats determined by transvaginal ultrasound at 12 weeks of gestation? SUMMARY ANSWER: Non-inferiority of oral dydrogesterone versus MVP was demonstrated at 12 weeks of gestation, with a difference in pregnancy rate and an associated confidence interval (CI) that were both within the non-inferiority margin. WHAT IS KNOWN ALREADY: MVP is routinely used in most clinics for luteal support in IVF, but it is associated with side effects, such as vaginal irritation and discharge, as well as poor patient acceptance. Dydrogesterone may be an alternative treatment due to its patient-friendly oral administration. STUDY DESIGN, SIZE, DURATION: Lotus I was an international Phase III randomized controlled trial, performed across 38 sites, from August 2013 to March 2016. Subjects were premenopausal women (>18 to <42 years of age; body mass index (BMI) ≥18 to ≤30 kg/m2) with a documented history of infertility who were planning to undergo IVF. A centralized electronic system was used for randomization, and the study investigators, sponsor's study team, and subjects remained blinded throughout the study. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 1031 subjects were randomized to receive either oral dydrogesterone (n = 520) or MVP (n = 511). Luteal support was started on the day of oocyte retrieval and continued until 12 weeks of gestation (Week 10), if a positive pregnancy test was obtained at 2 weeks after embryo transfer. MAIN RESULTS AND THE ROLE OF CHANCE: In the full analysis set (FAS), 497 and 477 subjects in the oral dydrogesterone and MVP groups, respectively, had an embryo transfer. Non-inferiority of oral dydrogesterone was demonstrated, with pregnancy rates at 12 weeks of gestation of 37.6% and 33.1% in the oral dydrogesterone and MVP treatment groups, respectively (difference 4.7%; 95% CI: -1.2-10.6%). Live birth rates of 34.6% (172 mothers with 213 newborns) and 29.8% (142 mothers with 158 newborns) were obtained in the dydrogesterone and MVP groups, respectively (difference 4.9%; 95% CI: -0.8-10.7%). Oral dydrogesterone was well tolerated and had a similar safety profile to MVP. LIMITATIONS, REASONS FOR CAUTION: The analysis of the results was powered to consider the clinical pregnancy rate, but the live birth rate may be of greater clinical interest. Conclusions relating to the differences between treatments in live birth rate, observed in this study, should therefore be made with caution. WIDER IMPLICATIONS OF THE FINDINGS: Oral dydrogesterone may replace MVP as the standard of care for luteal phase support in IVF, owing to the oral route being more patient-friendly than intravaginal administration, as well as it being a well tolerated and efficacious treatment. STUDY FUNDING/COMPETING INTEREST(S): Sponsored and supported by Abbott Established Pharmaceuticals Division. H.T.'s institution has received grants from Merck, MSD, Goodlife, Cook, Roche, Besins, Ferring and Mithra (now Allergan) and H.T. has received consultancy fees from Finox, Ferring, Abbott, ObsEva and Ovascience. G.S. has nothing to disclose. E.K. is an employee of Abbott GmbH. G.G. has received investigator fees from Abbott during the conduct of the study; outside of this submitted work, G.G. has received personal fees and non-financial support from MSD, Ferring, Merck-Serono, Finox, TEVA, Glycotope, as well as personal fees from VitroLife, NMC Healthcare LLC, ReprodWissen LLC and ZIVA LLC. TRIAL REGISTRATION NUMBER: NCT01850030 (clinicaltrials.gov). TRIAL REGISTRATION DATE: 19 April 2013. DATE OF FIRST PATIENT'S ENROLLMENT: 23 August 2013.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Tournaye H, Sukhikh GT, Kahler E, et al. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017. PMID: 28333318. doi:10.1093/humrep/dex023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。